Novonesis (Novozymes) A/S (NSIS-B) - Total Assets

Latest as of March 2026: Dkr16.52 Billion DKK ≈ $2.59 Billion USD

Based on the latest financial reports, Novonesis (Novozymes) A/S (NSIS-B) holds total assets worth Dkr16.52 Billion DKK (≈ $2.59 Billion USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.

Novonesis (Novozymes) A/S - Total Assets Trend (2002–2025)

This chart illustrates how Novonesis (Novozymes) A/S's total assets have evolved over time, based on quarterly financial data. Also see how much is Novonesis (Novozymes) A/S worth for the company's overall valuation and market capitalisation.

Novonesis (Novozymes) A/S - Asset Composition Analysis

Current Asset Composition (December 2025)

Novonesis (Novozymes) A/S's total assets of Dkr16.52 Billion consist of 12.1% current assets and 87.9% non-current assets. Review NSIS-B total liabilities to assess the company's total debt and financial obligations.

Asset Category Amount (DKK) % of Total Assets
Cash & Equivalents Dkr0.00 1.7%
Accounts Receivable Dkr869.40 Million 5.3%
Inventory Dkr772.20 Million 4.7%
Property, Plant & Equipment Dkr0.00 0.0%
Intangible Assets Dkr4.90 Billion 29.9%
Goodwill Dkr6.19 Billion 37.9%

Asset Composition Trend (2002–2025)

This chart illustrates how Novonesis (Novozymes) A/S's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See today's stock price for Novonesis (Novozymes) A/S for real-time trading data and today's change.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Novonesis (Novozymes) A/S's current assets represent 12.1% of total assets in 2025, a decrease from 45.2% in 2002.
  • Cash Position: Cash and equivalents constituted 1.7% of total assets in 2025, down from 10.0% in 2002.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 66.0% of total assets, an increase from 6.0% in 2002.
  • Asset Diversification: The largest asset category is goodwill at 37.9% of total assets.

Novonesis (Novozymes) A/S Competitors by Total Assets

Key competitors of Novonesis (Novozymes) A/S based on total assets are shown below.

Company Country Total Assets
Zhejiang Longsheng Group Co Ltd
SHG:600352
China CN¥76.50 Billion
Ningbo Shanshan Co Ltd
SHG:600884
China CN¥45.88 Billion
GCH Technology Co. Ltd. A
SHG:688625
China CN¥3.20 Billion
Jiangsu Ruitai New Energy Materials Co. Ltd.
SHE:301238
China CN¥9.46 Billion
Chongqing Zaisheng Tech Corp
SHG:603601
China CN¥3.19 Billion
Anhui Guofeng Plastic Industry Co Ltd
SHE:000859
China CN¥4.56 Billion
Daxin Materials Corp
TW:5234
Taiwan NT$4.84 Billion
Sino-High (China) Co. Ltd.
SHE:301076
China CN¥1.29 Billion

Novonesis (Novozymes) A/S - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 1.67 1.66 1.44
Quick Ratio 1.03 1.04 0.89
Cash Ratio 0.00 0.00 0.00
Working Capital Dkr823.27 Million Dkr775.70 Million Dkr2.15 Billion

Novonesis (Novozymes) A/S - Advanced Valuation Insights

This section examines the relationship between Novonesis (Novozymes) A/S's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 2.16
Latest Market Cap to Assets Ratio 1.72
Asset Growth Rate (YoY) 7.6%
Total Assets Dkr16.35 Billion
Market Capitalization $28.13 Billion USD

Valuation Analysis

Above Book Valuation: The market values Novonesis (Novozymes) A/S's assets above their book value (1.72x), reflecting positive investor sentiment about the company's future prospects.

Positive Asset Growth: Novonesis (Novozymes) A/S's assets grew by 7.6% over the past year, showing continued investment in the company's operational capacity.

Annual Total Assets for Novonesis (Novozymes) A/S (2002–2025)

The table below shows the annual total assets of Novonesis (Novozymes) A/S from 2002 to 2025.

Year Total Assets Change
2025-12-31 Dkr16.35 Billion
≈ $2.56 Billion
+7.59%
2024-12-31 Dkr15.20 Billion
≈ $2.38 Billion
-46.48%
2023-12-31 Dkr28.39 Billion
≈ $4.44 Billion
+1.46%
2022-12-31 Dkr27.98 Billion
≈ $4.38 Billion
+12.99%
2021-12-31 Dkr24.77 Billion
≈ $3.87 Billion
+20.76%
2020-12-31 Dkr20.51 Billion
≈ $3.21 Billion
+0.36%
2019-12-31 Dkr20.44 Billion
≈ $3.20 Billion
+3.76%
2018-12-31 Dkr19.70 Billion
≈ $3.08 Billion
+7.21%
2017-12-31 Dkr18.37 Billion
≈ $2.87 Billion
-1.53%
2016-12-31 Dkr18.66 Billion
≈ $2.92 Billion
+4.88%
2015-12-31 Dkr17.79 Billion
≈ $2.78 Billion
-3.45%
2014-12-31 Dkr18.43 Billion
≈ $2.88 Billion
+11.63%
2013-12-31 Dkr16.51 Billion
≈ $2.58 Billion
+9.22%
2012-12-31 Dkr15.11 Billion
≈ $2.36 Billion
+9.18%
2011-12-31 Dkr13.84 Billion
≈ $2.17 Billion
+9.92%
2010-12-31 Dkr12.59 Billion
≈ $1.97 Billion
+15.64%
2009-12-31 Dkr10.89 Billion
≈ $1.70 Billion
+9.72%
2008-12-31 Dkr9.93 Billion
≈ $1.55 Billion
+11.88%
2007-12-31 Dkr8.87 Billion
≈ $1.39 Billion
+11.37%
2006-12-31 Dkr7.96 Billion
≈ $1.25 Billion
+8.98%
2005-12-31 Dkr7.31 Billion
≈ $1.14 Billion
+2.45%
2004-12-31 Dkr7.13 Billion
≈ $1.12 Billion
-6.54%
2003-12-31 Dkr7.63 Billion
≈ $1.19 Billion
-8.59%
2002-12-31 Dkr8.35 Billion
≈ $1.31 Billion
--

About Novonesis (Novozymes) A/S

CO:NSIS-B Denmark Specialty Chemicals
Market Cap
$28.13 Billion
Dkr179.80 Billion DKK
Market Cap Rank
#957 Global
#7 in Denmark
Share Price
Dkr435.90
Change (1 day)
-0.16%
52-Week Range
Dkr342.00 - Dkr463.00
All Time High
Dkr508.57
About

Novozymes A/S produces and sells industrial enzymes, functional proteins, and microorganisms in Denmark, rest of Europe, North America, the Asia Pacific, the Middle East, Africa, and Latin America. It provides biosolutions for the food and beverage industry, such as dairy, baking, beverage, meat, plant-based, functional, and other foods, as well as precision protein and early lie nutrition. The c… Read more